Recording of hormone therapy and breast density in breast screening programs: summary and recommendations of the International Cancer Screening Network
- 114 Downloads
Breast density and the use of hormone therapy (HT) for menopausal symptoms alter the risk of breast cancer and both factors influence screening mammography performance. The International Cancer Screening Network (ICSN) surveyed its 29 member countries and found that few programs record breast density or the use of HT among screening participants. This may affect the ability of programs to assess their effectiveness in reducing breast cancer mortality. Seven countries recorded the use of HT at screening, and some were able to link screening records to individual prescribing records of HT. Eight countries reported recording breast density at screening mammography for some or all women screened. The recommendations of the ICSN for recording information about breast density and HT are presented.
KeywordsBreast screening Breast density Hormone therapy Program monitoring
We gratefully acknowledge the following members of the International Cancer Screening Network who provided information about their screening programs: Julianne Quaine (Australia), Ronaldo Silva Correa (Brazil), Jay Onysko (Canada), Adam Svoboknik (Czech Republic), Elsebeth Lynge (Denmark), Dominik Deitz (Germany), Gad Rennert (Israel), Noriaki Hiroshi (Japan), Won Chul Lee (Korea), Jacques Fracheboud (Netherlands), Solveig Hofvind (Norway), Jean-Luc Bulliard (Switzerland), Sue Moss (United Kingdom), Rod Walker (United States), and Gonzalo Pou (Uruguay). We also thank Gretchen Keel at Information Management Systems, Inc. for her programing support for the development and synopsis of the web survey, and Kathy Sedgwick at NOVA Research Company for her logistical support for the working group. Brian Cox was supported by the Director’s Cancer Research Trust. We also acknowledge funding support for this project from the National Cancer Institute, National Institutes of Health, United States. This study was partially supported by the National Cancer Institute Breast Cancer Surveillance Consortium (BCSC) (U01CA63740, U01CA86076, U01CA86082, U01CA63736, U01CA70013, U01CA69976, U01CA63731, U01CA70040).
Conflicts of interest
- 3.Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet 347(9017):1713–1727CrossRefGoogle Scholar
- 20.American College of Radiology (2003) American College of Radiology (ACR) Breast Imaging Reporting and Data System Atlas (BI-RADS® Atlas). American College of Radiology, Reston, VAGoogle Scholar
- 21.Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350(9084):1047–1059CrossRefGoogle Scholar
- 26.Kerlikowske K, Miglioretti DL, Buist DSM, Walker R, Carney PA, National Cancer Institute-Sponsored Breast Cancer Surveillance Consortium (2007) Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 99(17):1335–1339CrossRefPubMedGoogle Scholar
- 31.Verkooijen HM, Koot VCM, Fioretta G, Van Der Heiden M, Schipper MEI, Rapiti E et al (2008) Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing two European populations. Breast Cancer Res Treat 107(3):389–395CrossRefPubMedGoogle Scholar
- 35.Greendale GA, Reboussin BA, Sie A et al (1999) Effects of estrogen and estrogen–progestin on mammographic parenchymal density. Ann Intern Med 130:262–269Google Scholar
- 39.Takata Y, Maskerinec G, Le Marchand L (2007) Breast density and polymorphisms in genes coding for CYPIA2 and COMT: the multiethnic cohort. BMC Cancer 7. www.biomedcentral.com/1471-2407/1477/1430
- 52.Rosenberg RD, Hunt WC, Williamson MR, Gilliland FD, Wiest PW, Kelsey CA et al (1998) Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183, 134 screening mammograms in Albuquerque, New Mexico. Radiology 209(2):511–518PubMedGoogle Scholar
- 54.Banks E, Reeves G, Beral V, Bull D, Crossley B, Simmonds M et al (2006) Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect. Breast Cancer Res 8(1):R8Google Scholar